The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.

Reviva targets Q4 2026 FDA feedback on brilaroxazine formulation

Nov 13, 2026 01:13 (2h ago)

Verifying

Reviva expects FDA feedback on brilaroxazine’s new formulation for the RECOVER-2 trial.
$17.5 million was Reviva’s cash and cash equivalents balance on September 30, 2026.
RECOVER-2 enrollment is expected in the first half of 2027, subject to additional financing.